AD Pipeline Watch: Lebrikizumab Improves Quality of Life in AD Patients
Lebrikizumab monotherapy improves quality of life (QoL) and mental health for patients with moderate-to-severe atopic dermatitis (AD), according to new data from ADvocate1 and ADvocate2 in Dermatology and Therapy. Lebrikizumab is a targeted interleukin (IL)-13 inhibitor under investigation in the U.S with a decision from the Food and Drug Administration (FDA) expected in the second half of […]